Timed walk as primary outcome measure of treatment response in clinical trials for HTLV-1-associated myelopathy: a feasibility study

Table 1 Detectable change calculations given fixed sample size for the 10MWT at 24 weeks

	Number of participants in one arm	Detectable change (%)
SD	Number of participants in one arm	Power 0.8	Power 0.9
0.2	20	16.62	18.97
	25	14.94	17.07
	30	13.68	15.65
	35	12.70	14.55
	40	11.91	13.65
	45	11.26	12.91
	50	10.70	12.27
0.26	20	21.05	23.93
	25	18.96	21.60
	30	17.41	19.85
	35	16.19	18.48
	40	15.20	17.37
	45	14.38	16.44
	50	13.68	15.65
0.3	20	23.87	27.06
	25	21.54	24.48
	30	19.80	22.54
	35	18.44	21.01
	40	17.33	19.76
	45	16.40	18.72
	50	15.61	17.83

ISSN: 2055-5784